Poor drug solubility or the need for controlled or modified release remain common formulation optimisation considerations in drug development.
However, traditional industry structures mean that this process is constrained by long timelines and reliance on predictive laboratory and preclinical models.
This seminar will explore how Quotient Sciences’ Translational Pharmaceutics® platform integrates formulation development, GMP manufacturing, and clinical testing to accelerate the selection and optimisation of commercial intent formulations; a capability that can be further enhanced by the application of machine learning to the formulation development process.
Join us for discussions dedicated to solubility enhancement, modified release, and AI-informed drug development.
Date: 26 November 2026
Time: 9:30
Venue: